Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Shares of Moderna Inc. MRNA inched 0.43% higher to $42.18 Friday, on what proved to be an all-around favorable trading ...

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have ...

In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day. This change lagged the S&P 500's 1.26% gain on the day. Elsewhere, the Dow saw an upswing ...

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $41.58 which represents a slight increase of $2.20 or 5.59% from the prior close of $39.38. The stock opened at $39.71 and touched a low ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

Moderna is a contrarian play for 2025, despite a rough 2024 as one of the worst-performing Nasdaq-100 stocks. Click here to ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Moderna faces index removal, stock plunge, vaccine challenges, and lawsuits, while focusing on R&D in oncology and rare diseases for future growth.

Key Takeaways U.S. equities were closing out 2024 by edging lower at midday after opening the session higher.Berkshire ...